Yutrepia™ (treprostinil) – New drug approval
May 23, 2025 - Liquidia Corporation announced the FDA approval of Yutrepia (treprostinil) inhalation powder, for the treatment of Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
Top